A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma (OCTAVA)
A Double-Blind Placebo-Controlled Comparative Randomized Clinical Study of the Efficacy and Safety of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma
Sponsor: Biocad
This PHASE3 trial investigates Melanoma and Melanoma (Skin) and is currently ongoing. Biocad leads this study, which shows 5 recorded versions since 2022 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
5 versions recorded-
Sep 2025 — Present [monthly]
Active Not Recruiting PHASE3
-
Mar 2025 — Sep 2025 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Sep 2024 — Mar 2025 [monthly]
Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE3
-
Mar 2023 — Jul 2024 [monthly]
Recruiting PHASE3
First recorded
Aug 2022
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Biocad
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Arkhangelsk, Russia , Babruysk, Belarus , Barnaul, Russia , Brest, Belarus , Chelyabinsk, Russia , Faridabad, India , Gatchina, Russia , Grodno, Belarus , Homyel, Belarus , Kazan', Russia and 29 more locations